Skip to content
Triangle logo TriangleGet started
← Non-Small Cell Lung Cancer

HEALTH PROFESSIONAL · SOURCE READING

NTRK inhibitors (for patients with NTRK fusions)

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC (First-Line Therapy)

Somatic gene fusions in NTRK occur across a range of solid tumors including in fewer than 0.5% of NSCLC tumors.[79,80] These fusions appear to occur more frequently in nonsmokers with lung adenocarcinoma.

Source links and citations

Continue within this section

Larotrectinib →Entrectinib →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice